1152172-07-0

Basic information

• Product Name: [Ir(2-phenylpyridine)2-(4,7-diphenyl-1,10-phenanthroline)]Cl
• CAS NO: 1152172-07-0
• Molecular Weight: 869.468
• Mol File: 1152172-07-0.mol

Chemical Properties

• CAS DataBase Reference: [Ir(2-phenylpyridine)2-(4,7-diphenyl-1,10-phenanthroline)]Cl(CAS DataBase Reference)
• NIST Chemistry Reference: [Ir(2-phenylpyridine)2-(4,7-diphenyl-1,10-phenanthroline)]Cl(1152172-07-0)
• EPA Substance Registry System: [Ir(2-phenylpyridine)2-(4,7-diphenyl-1,10-phenanthroline)]Cl(1152172-07-0)

Safety Data

• Hazardous Substances Data: 1152172-07-0(Hazardous Substances Data)

Upstream product

• 1662-01-7 bathophenanthroline 
• 1413974-24-9 [Ir(2-phenylpyridinato)2(μ-Cl)]2 
• 1008-89-5 2-phenylpyridine 

Relevant articles and documents

Membrane localized iridium(III) complex induces endoplasmic reticulum stress and mitochondria-mediated apoptosis in human cancer cells

The cellular behavior and toxicity effect of organometallic complexes depend largely on their peripheral ligands. In this study, we have synthesized a series of novel luminescent cationic iridium(III) complexes by tuning the ancillary Na?§N ligand based on a structure [Ir(ppy)2(Na?§N)]+ (ppy = 1-phenyl-pyridine; Na?§N = 2,2′-bipyridine (bpy, 1) or phenanthroline (phen, 2) or 4,7-diphenyl-1,10-phenanthroline (DIP, 3)). As the size of coordinated Na?§N ligand increases, absorbance/emission efficiency, quantum yields, lipophilicity, and cell uptake rates of the complexes also increase, in a general order: 3 > 2 > 1. All three complexes display anticancer activity, with 3 exhibiting the highest cellular uptake efficiency and the greatest cytotoxic activities in several cancer cell lines with IC50s lower than that of cisplatin. Because of its strong hydrophobic nature, the death inducer 3 was found to accumulate favorably to endoplasmic reticulum (ER) and to cause ER stress in cells. The fast cytosolic release of calcium from stressed ER disturbed the morphology and function of mitochondria, initiating an intrinsic apoptotic pathway. Understanding of the cell death mechanism would help further structure-activity optimization on these novel Ir(III) complexes as emerging cancer therapeutics.

Sublimable Cationic Iridium(III) Complexes with 1,10-Phenanthroline Derivatives as Ancillary Ligands for Highly Efficient and Polychromic Electroluminescence

A novel series of four sublimable cationic iridium(III) complexes have been prepared with 1,10-phenanthroline derivatives as ancillary ligands and the same negative counter-ion, tetrakis[3,5-bis(trifluoromethyl)phenyl]borate, which has a large steric hindrance and widely dispersed charges, thereby increasing the ionic radii, reducing the electrostatic interaction, and thus improving the volatility. Their structural, photophysical, electrochemical, and thermal properties have been fully characterized. Upon excitation, these compounds show polychromic emission varying from green to orange in solution, which are blue-shifted in the solid state to different extents due to π–π conjugate effects in the ancillary ligands and the resulting molecular aggregation. OLEDs fabricated by vacuum evaporation deposition demonstrated desirable device performance with high efficiency and brightness, exhibiting various electroluminescent colors dependent upon doping concentration.

Protein Staining Agents from Cationic and Neutral Luminescent Iridium(III) Complexes

Seven luminescent iridium(III) complexes were prepared to investigate the relationships between chemical structures and properties of protein staining. For the first time, the effect of the main ligand, the π conjugation effect of the ancillary ligand, an